Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Psychopharmacology May 1, 2022 Sam Craft, Jason Ferris, Monica J Barratt et al. 19 citations
Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a greater risk of problematic use and withdrawal. This study aimed to characterise the withdrawal symptom profile of SCRAs and compare their profile of effect with high-potency herbal cannabis. Global Drug Survey data (2015 and 2016) were used to access a clinically...
DOI: 10.1007/s00213-021-05945-1 (opens in new tab)
Full text (opens in new tab)
Cannabis
Abuse liability
Effect profile
Scra
+3